Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy

Clinical Cancer Research

Volumn 13, Issue 16, 2007, Pages 4800-4806

  Bedrosian, Isabelle ^a   Lee, Christine ^a   Tucker, Susan L ^a   Palla, Shana L ^a   Lu, Karen ^a   Keyomarsi, Khandan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE 2; CYCLIN E; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; PHOSPHOTRANSFERASE; PROTEIN P21; PROTEIN P27; TAXANE DERIVATIVE; TOPOTECAN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; CYCLIN E; CYCLIN-DEPENDENT KINASES; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 34548080298     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0142     Document Type: Article

References (30)

1. 1 in mammalian fibroblasts. Science 1993;259:1908-12.
2. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 2004;23:2648-57.
3. Akli S, Zheng PJ, Multani AS, et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004;64:3198-208.
4. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297-300.
5. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-7.
6. Bani-Hani KE, Almasri NM, Khader YS, Sheyab FM, Karam HN. Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer. Clin Cancer Res 2005;11:1447-53.
7. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 1996;69:247-53.
8. Farley J, Smith LM, Darcy KM, et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res 2003;63:1235-41.
9. Ferreri AJ, Ponzoni M, Pruneri G, et al. Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. Int J Cancer 2001;94:599-604.
10. Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res 2000;60:242-4.
11. Jang SJ, Park YW, Park MH, et al. Expression of cell-cycle regulators, cyclin E and p21WAF1/CIP1, potential prognostic markers for gastric cancer. Eur J Surg Oncol 1999;25:157-63.
12. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
13. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
14. Rosen DG, Yang G, Deavers MT, et al. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 2006;106:1925-32.
15. Tissier F, Louvel A, Grabar S, et al. Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. Eur J Endocrinol 2004;150:809-17.
16. Porter D, Keyomarsi K. Novel splice variants of cyclin E with altered substrate specificity. Nucl Acids Res 2000;28:E101.
17. Porter D, Zhang N, Danes C, et al. Tumor Specific Proteolytic Processing of Cyclin E Generates Hyper-Active Lower Molecular Weight Forms. Mol Cell Biol 2001;21:6254-69.
18. Marone M, Scambia G, Giannitelli C, et al. Analysis of Cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. Int J Cancer 1998;75:34-9.
19. Sawasaki T, Shigemasa K, Shiroyama Y, et al. Cyclin E overexpression in epithelial ovarian cancers: inverse correlation with p53 protein accumulation. J Soc Gynecol Investig 2001;8:179-85.
20. Shimizu M, Nikaido T, Toki T, Shiozawa T, Fujii S. Clear Cell Carcinoma Has an Expression Pattern of Cell Cycle Regulatory Molecules that is Unique among Ovarian Adenocarcinomas. Cancer 1999;85:669-77.
21. Sui L, Dong Y, Ohno M, et al. Implication of Malignancy and Prognosis of p27(kip1), Cyclin E and CDK2 Expression in Epithelial Ovarian Tumors. Gynecol Oncol 2001;83:56-63.
22. Milde-Langosch K, Hagen M, Bamberger AM, Loning T. Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer. Int J Gynecol Pathol 2003;22:168-74.
23. Rosenberg E, Demopoulos R, Zeleniuch-Jacquotte A, et al. Expression of cell cycle regulators p57(KIP2), cyclin D1 and cyclin E in epithelial ovarian tumors and survival. Human Pathol 2001;32:808-13.
24. 1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998;17:2393-402.
25. Chappuis PO, Donato E, Goffin JR, et al. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol 2005;16:735-42.
26. Goto Y, Kawauchi S, Ihara K, et al. The prognosis in spindle-cell sarcoma depends on the expression of cyclin-dependent kinase inhibitor p27(Kip1) and cyclin E. Cancer Sci 2003;94:412-7.
27. Han S, Park K, Bae BN, et al. Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer. J Surg Oncol 2003;83:241-7.
28. Geng Y, Yu Q, Sicinska E, et al. Cyclin E ablation in the mouse. Cell 2003;114:431-43.
29. Matsumoto Y, Maller JL. A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry. Science 2004;306:885-8.
30. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.